Galectin Therapeutics to Present New Data on the Treatment of Liver Fibrosis and Cirrhosis

 Galectin Therapeutics to Present New Data on the Treatment of Liver Fibrosis
                                and Cirrhosis

-- Abstract Accepted for Presentation at the International Liver Congress 2013

PR Newswire

NORCROSS, Ga., April 17, 2013

NORCROSS, Ga., April 17, 2013 /PRNewswire/ --Galectin Therapeutics (NASDAQ:
GALT), the leading developer of therapeutics that target galectin proteins to
treat fibrosis and cancer, today announced that its abstract was accepted by
the European Association for the Study of the Liver for presentation on April
27, 2013 at the International Liver Congress to be held in Amsterdam, The
Netherlands. The abstract, "Regression of fibrosis and reversal of cirrhosis
in thioacetamide-induced liver fibrosis following treatment with galectin
inhibitors"  provides evidence in a pre-clinical model that Galectin's drugs
are able to reverse established fibrosis and cirrhosis.

"Data continues to accumulate showing the effectiveness of our galectin
inhibitor drugs in pre-clinical models," said Dr. Peter G. Traber, President,
Chief Executive Officer and Chief Medical Officer, Galectin Therapeutics.
"Research will be presented on how both GR-MD-02 and GM-CT-01 are effective in
reversing fibrosis and cirrhosis in established disease. The findings add
confidence for the possibility of this mechanism extending to human disease.
Following the presentation, additional information will be announced and the
data will be posted on the Galectin website."

About Galectin Therapeutics
Galectin Therapeutics (NASDAQ: GALT) is developing promising
carbohydrate-based therapies for the treatment of fibrotic liver disease and
cancer based on the Company's unique understanding of galectin proteins, key
mediators of biologic function. We are leveraging extensive scientific and
development expertise as well as established relationships with external
sources to achieve cost effective and efficient development. We are pursuing a
clear development pathway to clinical enhancement and commercialization for
our lead compounds in liver fibrosis and cancer. Additional information is
available at 

Forward Looking Statements
This press release contains, in addition to historical information,
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements relate to future events or
future financial performance, and use words such as "may," "estimate,"
"could," "expect" and others. They are based on our current expectations and
are subject to factors and uncertainties which could cause actual results to
differ materially from those described in the statements. Factors that could
cause our actual performance to differ materially from those discussed in the
forward-looking statements include, among others: incurrence of operating
losses since our inception, uncertainty as to adequate financing of our
operations, extensive and costly regulatory oversight that could restrict or
prevent product commercialization, inability to achieve commercial product
acceptance, inability to protect our intellectual property, dependence on
strategic partnerships, product competition, and others stated in risk factors
contained in our SEC filings. We cannot assure that we have identified all
risks or that others may emerge which we do not anticipate. You should not
place undue reliance on forward-looking statements. Although subsequent events
may cause our views to change, we disclaim any obligation to update
forward-looking statements.

SOURCE Galectin Therapeutics Inc.

Contact: Galectin Therapeutics Inc., Peter G. Traber, Chief Executive Officer,
(678) 620-3186,
Press spacebar to pause and continue. Press esc to stop.